Back to workflow browser

First-pass extracted concept

bedside-to-bench-to-bedside translational resistance-artery remodeling workflow

Candidate: workflow template1 source documents4 linked claims1 workflow observations4 stage observations3 step observations
Jump to workflow stagesJump to workflow logicJump to workflow stepsJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

bedside to bench research, bedside to bench to bedside

Workflow Stage Observations

Stage 1functional characterizationcell basedSource 1DOIPubMed

Clinical phenotype definition in hypertensive humans

Why this stage exists: The review frames bedside observations as the starting point because the key human vascular abnormalities are known clinically, but their causes remain uncertain.

Selection basis: Identify human resistance-artery remodeling and altered reactivity as clinically relevant phenotypes requiring mechanistic explanation.

Advance criteria: Observed human remodeling and altered reactivity motivate extension to bench studies.

Enriches for: media-to-lumen ratio, reduced lumen, endothelial dysfunction, clinical prognostic relevance

Stage 2library buildcell basedSource 1DOIPubMed

Acquisition of human resistance arteries and derived vascular smooth muscle cells

Why this stage exists: The review states that ideally one should examine cells directly involved in the pathological process and presents the gluteal biopsy-derived system as a way to do this.

Selection basis: Obtain disease-relevant human small arteries and low-passaged derived cells from well-characterized subjects.

Advance criteria: Use isolated vessels and derived vascular smooth muscle cells for mechanistic study.

Bottleneck risk: Ethical and practical constraints limit direct access to human vascular cells.

Higher fidelity: yes

Enriches for: human disease relevance, resistance-artery specificity, preserved cell morphology, preserved cell function

Guards against: poor relevance of large-vessel samples, confounding from postmortem or surgical source variability, phenotypic mismatch of circulating blood cells

Stage 3functional characterizationcell basedSource 1DOIPubMed

Bench mechanistic dissection in isolated vessels, derived cells, and animal vessels

Why this stage exists: The review explicitly says bedside findings should be extended to the bench to study underlying molecular and cellular processes.

Selection basis: Study molecular and cellular processes underlying vascular changes in tractable in vitro and experimental systems.

Advance criteria: Mechanistic insights identify putative genes, proteins, and pathways that could be targeted therapeutically.

Higher fidelity: yes

Enriches for: AT1 receptor signaling, reactive oxygen species generation, NADPH oxidase activation, growth, fibrosis, inflammation, apoptosis

Stage 4confirmatory validationcell basedSource 1DOIPubMed

Return-to-bedside therapeutic testing of mechanism-blocking agents

Why this stage exists: The review's translational goal is to echo findings back to the bedside and test novel therapeutic strategies developed through experimentation.

Selection basis: Test agents that block implicated mechanisms, especially inhibitors of the renin-angiotensin system, for effects on vascular remodeling in hypertensive humans.

Advance criteria: Demonstration that mechanism-blocking agents improve human vascular structure and function.

Higher fidelity: yes

Enriches for: small-artery structural correction, endothelial function improvement, clinical translational relevance

Preserves downstream axes: human therapeutic relevance

Workflow Logic

Workflow evidenceSource 1

Objective: Translate human observations of resistance-artery remodeling in hypertension into mechanistic understanding and then back into therapeutic testing.

Why it works: The review explicitly argues that uncertain clinical observations should be extended to bench systems where molecular and cellular processes can be studied, then returned to humans to test agents that block the implicated mechanisms.

Priority logic: The workflow starts from human pathology to define the relevant phenotype, moves to bench systems to resolve mechanism under more tractable conditions, and then returns to patients to test whether blocking those mechanisms improves vascular remodeling.

Validation strategy: Use human small-artery remodeling observations, mechanistic studies in derived human vascular smooth muscle cells and experimental animal vessels, and then clinical studies of inhibitors of the renin-angiotensin system.

Target properties: small-artery structure, media-to-lumen ratio, endothelial function, vascular smooth muscle cell signaling, vascular remodeling

Target mechanisms: renin-angiotensin system signaling, AT1 receptor signaling, reactive oxygen species generation, NADPH oxidase activation, fibrosis, inflammation, apoptosis

Target techniques: human tissue biopsy, isolated vessel study, vascular smooth muscle cell derivation, animal model comparison, therapeutic mechanism blockade

Workflow Step Observations

Step 1analysisSource 1

Observe resistance-artery remodeling and altered reactivity in hypertensive patients

Purpose: Define the human vascular phenotype that needs mechanistic explanation.

Why now: The review presents bedside observations as the starting point for the translational itinerary.

Validation focus: Human relevance of the remodeling phenotype

Targets properties: remodeling, altered reactivity, endothelial dysfunction

Step 2assaySource 1

Extend bedside findings to bench systems to study molecular and cellular mechanisms

Purpose: Resolve how vascular changes occur and identify signaling pathways contributing to remodeling.

Why now: The review states that human observations alone leave causality and mechanism uncertain, so bench systems are needed next.

Decision gate: Mechanistic uncertainty in human observations motivates transition to isolated vessels, cells, and animal models.

Targets properties: cellular signaling, growth, fibrosis, inflammation, oxidative stress

Step 3decisionSource 1

Test mechanism-blocking therapies back in humans

Purpose: Evaluate whether therapies targeting the implicated mechanisms improve vascular remodeling in patients.

Why now: The review explicitly places therapeutic testing after mechanistic insights are gained at the bench.

Validation focus: Clinical translation of mechanistic findings

Targets properties: small-artery structure, endothelial function

Evidence Snippets

We will recapitulate our own scientific itinerary from the bedside and studies of human small artery remodeling to the bench and the use of cells derived from these human small arteries as well as cells from vessels from experimental animals, and with the insights gained in the latter, back to the bedside, with studies of the action of agents that block these mechanisms.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1clinical frequency summarysupports2004Source 1DOIPubMed

Approximately 60% of hypertensive patients exhibit endothelial dysfunction already in stage 1 hypertension.

Quoted textsource-backed
Approximately 60% of hypertensive patients exhibit endothelial dysfunction already in stage 1 hypertension.
Claim 2mechanism summarysupports2004Source 1DOIPubMed

ANG II, aldosterone, and endothelin exert remodeling effects largely through NADPH oxidase activation and to a lesser degree through xanthine oxidase and mitochondrial reactive oxygen species generation.

Quoted textsource-backed
ANG II, aldosterone, and endothelin exert remodeling effects in large measure by activation of NADPH oxidase, and to lesser degree by stimulating xanthine oxidase and mitochondrial reactive oxygen species generation.
Claim 3mechanism summarysupports2004Source 1DOIPubMed

AT1 receptor stimulation increases reactive oxygen species partly via c-src, PKC, and phospholipase D and contributes to endothelial dysfunction by inactivating nitric oxide.

Quoted textsource-backed
Stimulation of angiotensin type 1 (AT1) receptors (AT1R) leads to increased reactive oxygen species in part via activation of nonreceptor tyrosine kinases such as c-src, and of PKC and phospholipase D, and thereby contributes to endothelial dysfunction by inactivating nitric oxide (NO).
Claim 4therapeutic summarysupports2004Source 1DOIPubMed

ACE inhibitors and angiotensin receptor blockers, but not beta-blockers, correct small artery structure and endothelial dysfunction in hypertensive patients.

Quoted textsource-backed
Treatment of hypertensive patients with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, but not β-blockers, corrects small artery structure and endothelial dysfunction